(Q42651945)

4 November 2017

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. (English)

1 reference

4 November 2017

0 references

A Todorova

1

1 reference

PubMed ID

11402632

4 November 2017

B Vonderheid-Guth

series ordinal

2

1 reference

PubMed ID

11402632

4 November 2017

W Dimpfel

series ordinal

3

1 reference

4 November 2017

1 June 2001

1 reference

The Journal of Clinical Pharmacology

4 November 2017

1 reference

4 November 2017

41

1 reference

4 November 2017

636-644

1 reference

4 November 2017

6

1 reference

Definition of overactive bladder and epidemiology of urinary incontinence

4 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

The patient with an overactive bladder--symptoms and quality-of-life issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Diagnosis and significance of idiopathic overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

M1 muscarinic antagonists interact with sigma recognition sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

IPEG guideline on statistical design and analysis for pharmacodynamic trials. International Pharmaco-EEG Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Reflection of mental exercise in the dynamic quantitative topographical EEG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Planning controlled clinical trials on the basis of descriptive data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Treatment of overactive bladder: other drug mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Muscarinic receptor antagonists in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

A neurologic basis for the overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Bladder distention activates noradrenergic locus coeruleus neurons by an excitatory amino acid mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Locus coeruleus activation by colon distention: role of corticotropin-releasing factor and excitatory amino acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

Locus coeruleus neurons and sympathetic nerves: activation by visceral afferents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010528

10.1177/00912700122010528

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference

PubMed ID

11402632